Fusion is at the forefront of scientific exploration, pioneering innovative precision medications tailored for cancer treatment. As a clinical-stage biopharmaceutical firm, we specialize in developing advanced radiopharmaceuticals as targeted cancer therapies. Leveraging our exclusive Fast-Clear™ linker technology, we have created the Targeted Alpha Therapies (TAT) platform to connect alpha particle-emitting isotopes to specific antibodies and other targeting agents, ensuring the precise delivery of treatments to tumor sites.